ContextVision (CONTX.OL) Aktie Kurs

ContextVision Kurs

Oslo Børs·LUKKET
4,80
​
Markedet lukket

Omsætningen er vokset med 4,0 % om året de seneste 19 år til 110,28 Mio. SEK. Indtjening pr. aktie er faldet med 10,3 % om året de seneste 19 år. ContextVisions nettoavance ligger på 0,7 %, op fra -7,8 % for flere år siden. ContextVision har i øjeblikket et direkteafkast på omkring 9,38 %. Udlodningsandelen er omkring 106 % af indtjeningen. Analytikernes mediankursmål er 4,29 SEK, hvilket er under den aktuelle kurs med 10,5 %. Af 7 analytikere anbefaler 0 køb — den samlede vurdering er Sælg.

ContextVision aktiekurs

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

ContextVision aktie og aktieanalyse

ContextVision AB er en global leverandør af software til medicinsk billeddannelse med speciale i udvikling og levering af avanceret software til anvendelse inden for radiologi, mammografi, ultralyd og digital patologi. Virksomheden tilbyder et bredt produktsortiment, herunder VOCAL til tredimensionel analyse af volumendata, GOPView® US til realtidsoptimering af ultralydsbilleder samt INIFY Prostate til analyse af vævsprøver vedrørende prostatacancer. Selskabet er engageret i løbende forbedring og innovation og samarbejder tæt med kunder og partnere om at udveksle ideer og integrere innovative teknologier i den moderne medicin.

Hyppigt stillede spørgsmål om ContextVision-aktien

The business model of ContextVision AB is focused on providing advanced medical imaging software solutions. The company develops and sells state-of-the-art image enhancement technologies for use in various medical imaging applications. ContextVision's software algorithms are designed to enhance image quality, optimize accuracy, and improve workflow efficiency. By partnering with leading original equipment manufacturers (OEMs) in the medical imaging industry, ContextVision aims to deliver innovative solutions that enable healthcare providers to obtain clearer and more accurate medical images. With a strong emphasis on research and development, ContextVision continuously strives to maintain its position as a trusted provider of advanced imaging solutions to improve patient care and diagnosis.

ContextVision AB is primarily active in the medical imaging industry.

The main competitors of ContextVision AB in the market include companies such as GE Healthcare, Siemens Healthineers, and Merge Healthcare. These companies also operate in the medical imaging and artificial intelligence software sectors, offering similar products and solutions. ContextVision AB strives to distinguish itself through its innovative technologies and advanced image enhancement solutions, ensuring enhanced image quality and accurate diagnoses for healthcare professionals. With a strong focus on research and development, ContextVision AB continuously aims to stay ahead of the competition and deliver cutting-edge software solutions to meet the evolving needs of the medical imaging industry.

ContextVision AB is a renowned company specializing in medical imaging software solutions. Established in 1983, the company has amassed a rich history and background in the medical technology domain. ContextVision AB focuses on developing innovative software, such as image enhancement, 3D visualization, and AI-based technologies, catering to healthcare providers and medical imaging equipment manufacturers globally. With its strong industry expertise and continuous research and development efforts, ContextVision AB has positioned itself as a leading provider of state-of-the-art imaging solutions. The company's dedication to quality and customer satisfaction has earned it a reputable name in the medical imaging industry.

ContextVision AB has successfully achieved several significant milestones over the years. Some noteworthy accomplishments include developing innovative software solutions for medical imaging, establishing strong partnerships with leading industry players, and receiving numerous prestigious awards for their cutting-edge technologies. Additionally, ContextVision AB has consistently demonstrated strong financial performance and growth, consolidating its position as a key player in the medical imaging market. These milestones highlight the company's commitment to innovation, excellence, and delivering value to its customers. ContextVision AB's achievements emphasize its reputation as a reliable and forward-thinking company in the field of medical imaging.

ContextVision AB is primarily present in several countries and regions. It has a strong presence in Europe, with a focus on Scandinavian countries such as Sweden, Norway, and Finland. The company also operates in other European regions including Germany and the United Kingdom. In addition to Europe, ContextVision AB has expanded its presence in the Asia-Pacific region, particularly in China and Japan. Furthermore, the company has a growing customer base in North America, particularly in the United States and Canada. ContextVision AB's global footprint allows it to cater to a wide range of customers and provide its innovative stock services worldwide.

ContextVision AB represents a strong set of values and corporate philosophy. The company is committed to delivering high-quality medical imaging software solutions to healthcare providers worldwide. ContextVision AB prioritizes innovation, collaboration, and customer satisfaction. With a strong focus on research and development, ContextVision AB continuously strives to enhance patient care and improve outcomes. By leveraging cutting-edge technology and expertise, the company aims to provide efficient and reliable solutions for medical image analysis and enhancement. ContextVision AB's commitment to excellence and customer-centric approach make it a trusted leader in the healthcare technology industry.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 4,29 SEK for ContextVision-aktien (median: 4,29 SEK), svarende til -10,5 % i forhold til seneste kurs. Konsensus bygger på 7 analytikervurderinger.

7 analytikere vurderer i øjeblikket ContextVision-aktien: 0 anbefaler køb, 3 hold og 4 salg. For 2026 forventer analytikere, at ContextVision genererer omsætning på 102,84 Mio. SEK og indtjening pr. aktie på 0,14 SEK.

Omregnet til den aktuelle valutakurs handles ContextVision-aktien til 0,44 EUR (4,80 SEK).

ContextVision-aktien (CONTX.OL) er noteret på 3 børser, herunder: London (0L8Z.L), Oslo (CONTX.OL).

ContextVision AB is a leading provider of innovative solutions in the field of medical imaging. The company was founded in 1983 and currently employs over 100 employees. It has been listed on the Nasdaq Stockholm since 1999 and is headquartered in Stockholm, Sweden. ContextVision consists of four business areas that focus on specific segments of medical imaging: digital pathology, ultrasound, mammography, and radiography. Each business area offers a wide range of products and services aimed at improving precision, efficiency, and patient care. The product portfolio of ContextVision is tailored to the needs of medical professionals and clinicians who rely on accurate analysis and diagnosis of images. For example, the company offers a state-of-the-art software platform for digital pathology, allowing pathologists to digitally capture, store, and analyze histological images and data. This improves the accuracy of diagnosis and increases efficiency in pathology laboratories. Another example is the company's ultrasound division, which focuses on improving image quality and precision in ultrasound diagnostics. Through its image enhancement technology, ContextVision provides more productive diagnostic solutions that are faster and more accurate than conventional ultrasound systems. The company also offers solutions for mammography that target the detection of smaller tumors. Together, these offerings not only improve patient care but also contribute to reducing medical errors. ContextVision gains market share through partnerships with leading manufacturers of medical imaging devices. The company leverages its unique expertise in image analysis and enhancement to develop innovative solutions in collaboration with its partners. This collaboration has, for example, led to the development of the "GOPiCE" concept, which represents a benchmark in digital pathology. The range of solutions allows customers to create more efficient diagnoses while ensuring higher accuracy and reliability in patient care. Overall, ContextVision has secured its leading position in the field of medical imaging through the continuity of its performance and its willingness to adapt to the needs of its customers and partners. The company is committed to improving medical imaging and supporting its customers through innovative solutions. ContextVision is a pioneer in image analysis and an important component in the medical field.

forventet-omsætningen for ContextVision er 102,84 Mio. SEK. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for ContextVision er 10,98 Mio. SEK. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for ContextVision er i øjeblikket 33,11. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af ContextVision-aktien.

Pris-til-salgs-forholdet (P/S) for ContextVision er i øjeblikket 3,54. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for ContextVision-aktien.

AlleAktien-kvalitetsscore for ContextVision er 1/10.

ISIN for ContextVision er SE0014731154. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for ContextVision er A2QA6S. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for ContextVision er CONTX.OL. Tickersymbolet bruges til at handle ContextVision-aktier på børsen.

Fair værdiTerminal
4,75 SEK
Over-/underværdieringTerminal
Fair værdieret
Sektor
Industri
Sundhedsteknologi
Antal aktier
Medarbeidere
Omsætning pr. medarbejder
2,40 Mio. SEK
Omsætningsvækst Ø5 år
EBIT-vækst Ø5 år
Resultatvækst Ø5 år
Land
Sverige
Valuta
SEK
Børsintroduktion
6. mar. 1997
ISIN
SE0014731154
CUSIP
W22435114
SEDOL
BKY41R1
Markedsværdi
52-ugers interval
AAQS
1 / 10
PEG-forhold
122,34
P/E-forhold
P/Ee 2026
33,19
P/Ee 2027
31,35
P/Ee 2028
29,70
P/S
P/Se
3,54
EV/EBIT
561,29
K/B-forhold
3,96
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0,78 %
Dividende
Dividendeafkast
0,00 %
Estimeret dividendeafkast
11,26 %
Udlodningsforhold
105,81 %
Dividendvækst Ø5Y
—
Dividender pr. år
1
Dividende udbetalt siden
0 år
Dividende ikke reduceret siden
0 år
Dividende øget siden
0 år
Källskat
30,00 %
Sidst opdateret 5. nov. 2026, 02.40

ContextVision Ticker

LONDON · 0L8Z.LLONDON STOCK EXCHANGE · 0L8Z.LOSLO · CONTX.OL

ContextVision FIGI

CONTX:NO · BBG000BRBD42COV1:XH · BBG000FY07T1COV1:XF · BBG000FY1BH4COV1:XE · BBG000FY1D62COV1:XL · BBG000FY1F58COV1:XG · BBG000FY1FW8COV1:XO · BBG000FY1G47COV1:XA · BBG000FY1K66COV1:XT · BBG000FY1LB8COV1:XW · BBG000FY1M35COV1:EU · BBG000FY1MW3COV1SEK:EU · BBG000GD26Z9